{"transactions":[{"id":853272,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-09T09:14:42.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":15.39,"value":107730.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The reported transaction reflects the open market purchase of shares of the Issuer's common stock. The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $15.35 to $15.42, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life (\"Aisling Capital\"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP (\"Aisling Arcturus\" and, together with Aisling Capital, \"Aisling\"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026.  Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein."}],"balance_after":2045730,"source":{"system":"sec-edgar","filing":"0001140361-26-008363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036126008363/form4.xml","form_type":"4"}},{"id":853271,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-09T09:14:42.000Z","date":"2026-03-05","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":15.67,"value":109690.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the \"Issuer\") common stock. The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive."},{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life (\"Aisling Capital\"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP (\"Aisling Arcturus\" and, together with Aisling Capital, \"Aisling\"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026.  Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein."}],"balance_after":2038730,"source":{"system":"sec-edgar","filing":"0001140361-26-008363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036126008363/form4.xml","form_type":"4"}},{"id":909721,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-11T21:00:09.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":17730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":17730,"derivative":{"exercise_price":16.37,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":17730},"source":{"system":"sec-edgar","filing":"0001140361-26-004885","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036126004885/form4.xml","form_type":"4"}},{"id":909720,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-11T21:00:09.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":10690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 81,885 shares of common stock owned by the Reporting Person."}],"balance_after":98020,"source":{"system":"sec-edgar","filing":"0001140361-26-004885","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036126004885/form4.xml","form_type":"4"}},{"id":994420,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T21:01:15.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":137330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":137330,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":137330},"source":{"system":"sec-edgar","filing":"0001104659-25-114081","document":"tm2531774-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925114081/tm2531774-1_4seq1.xml","form_type":"4"}},{"id":994419,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T21:01:15.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":84411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":84411,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":84411},"source":{"system":"sec-edgar","filing":"0001104659-25-114081","document":"tm2531774-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925114081/tm2531774-1_4seq1.xml","form_type":"4"}},{"id":1081998,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:30:06.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":0,"derivative":{"exercise_price":0.3051,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-020239","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588925020239/form4-07242025_040701.xml","form_type":"4"}},{"id":1081997,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:30:06.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":0,"derivative":{"exercise_price":3.35,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-020239","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588925020239/form4-07242025_040701.xml","form_type":"4"}},{"id":1081996,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:30:06.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":0,"derivative":{"exercise_price":1.47,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":31238},"source":{"system":"sec-edgar","filing":"0001415889-25-020239","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588925020239/form4-07242025_040701.xml","form_type":"4"}},{"id":1081995,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:30:06.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15619,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":0,"derivative":{"exercise_price":1.31,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":15619},"source":{"system":"sec-edgar","filing":"0001415889-25-020239","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588925020239/form4-07242025_040701.xml","form_type":"4"}},{"id":1081994,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T16:30:06.000Z","date":"2025-07-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.36 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":31238},"source":{"system":"sec-edgar","filing":"0001415889-25-020239","document":"form4-07242025_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588925020239/form4-07242025_040701.xml","form_type":"4"}},{"id":1109593,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":37541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":5.4,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":37541},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109592,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":51630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":3.35,"expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":51630},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109591,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":53172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":1.67,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":53172},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109590,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":2.35,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109589,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":2.915,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109588,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":3.89,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109587,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":4.91,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109586,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":53837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":3.66,"expiration_date":"2027-06-06","underlying":"Common Stock","underlying_shares":53837},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109585,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109584,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":5.96,"expiration_date":"2026-01-28","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109583,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":194749,"price":20.24,"value":3941719.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.40, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 76,441 shares of common stock owned by the reporting person."}],"balance_after":87330,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109582,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":137931,"price":20.82,"value":2871723.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.39, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 271,190 shares of common stock owned by the reporting person."}],"balance_after":282079,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109581,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":37541,"price":5.4,"value":202721.4,"ownership":{"direct":true},"balance_after":420010,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109580,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":51630,"price":3.35,"value":172960.5,"ownership":{"direct":true},"balance_after":382469,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109579,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":53172,"price":1.67,"value":88797.24,"ownership":{"direct":true},"balance_after":330839,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109578,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":55000,"price":2.35,"value":129250.0,"ownership":{"direct":true},"balance_after":277667,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109577,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.915,"value":43725.0,"ownership":{"direct":true},"balance_after":222667,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109576,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":3.89,"value":116700.0,"ownership":{"direct":true},"balance_after":207667,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109575,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":17500,"price":4.91,"value":85925.0,"ownership":{"direct":true},"balance_after":177667,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109574,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":53837,"price":3.66,"value":197043.42,"ownership":{"direct":true},"balance_after":160167,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109573,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":5,"value":50000.0,"ownership":{"direct":true},"balance_after":106330,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109572,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":9000,"price":5.96,"value":53640.0,"ownership":{"direct":true},"balance_after":96330,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1109571,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-16T21:00:32.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":92941,"price":21.69,"value":2015890.29,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $22.17, inclusive.  The reporting person undertakes to provide to ADMA Biologics, Inc. (the \"Issuer\"), any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein."}],"balance_after":2031730,"source":{"system":"sec-edgar","filing":"0001140361-25-022713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125022713/form4.xml","form_type":"4"}},{"id":1117575,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T16:20:33.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":35000,"derivative":{"exercise_price":0.3051,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-016253","document":"form4-06092025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588925016253/form4-06092025_040614.xml","form_type":"4"}},{"id":1252481,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-21T21:05:29.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":16279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":16279,"derivative":{"exercise_price":16.07,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":16279},"source":{"system":"sec-edgar","filing":"0001140361-25-005541","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125005541/form4.xml","form_type":"4"}},{"id":1252480,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-21T21:05:29.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":10889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 RSUs granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (iii) 64,421 shares of common stock owned by the reporting person."}],"balance_after":87330,"source":{"system":"sec-edgar","filing":"0001140361-25-005541","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036125005541/form4.xml","form_type":"4"}},{"id":1268100,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-14T22:20:34.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-014321","document":"tm256716-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014321/tm256716-7_4seq1.xml","form_type":"4"}},{"id":1322178,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-26T21:01:17.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":11085,"price":3.2,"value":35472.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reportable securities are directly owned by Aisling Capital IV, LP (\"Aisling\"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are directly owned by Aisling Capital IV, LP (\"Aisling\"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose."}],"balance_after":325370,"source":{"system":"sec-edgar","filing":"0001104659-24-131704","document":"tm2432058-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924131704/tm2432058-1_4seq1.xml","form_type":"4"}},{"id":1347012,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-02T21:02:40.000Z","date":"2024-11-27","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person is exercising these options due to their near-term expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vested monthly over a period of 24 months from the date of grant, becoming fully vested on January 30, 2017."}],"balance_after":0,"derivative":{"exercise_price":10.8,"expiration_date":"2025-01-30","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-24-048224","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124048224/form4.xml","form_type":"4"}},{"id":1347011,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-12-02T21:02:40.000Z","date":"2024-11-27","kind":"exercise","planned":false,"acquired":true,"shares":9000,"price":10.8,"value":97200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein."}],"balance_after":2124671,"source":{"system":"sec-edgar","filing":"0001140361-24-048224","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124048224/form4.xml","form_type":"4"}},{"id":1477018,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T16:26:42.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":35000,"derivative":{"exercise_price":3.35,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-24-017197","document":"form4-06172024_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000141588924017197/form4-06172024_080638.xml","form_type":"4"}},{"id":1568042,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-19T21:48:01.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":411829,"price":6.08,"value":2503920.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.17. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon."}],"balance_after":2115671,"source":{"system":"sec-edgar","filing":"0001140361-24-014226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124014226/form4.xml","form_type":"4"}},{"id":1568041,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-19T21:48:01.000Z","date":"2024-03-18","kind":"sale","planned":false,"acquired":false,"shares":49887,"price":6.01,"value":299820.87,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon."}],"balance_after":2527500,"source":{"system":"sec-edgar","filing":"0001140361-24-014226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124014226/form4.xml","form_type":"4"}},{"id":1574451,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-15T21:00:30.000Z","date":"2024-03-15","kind":"sale","planned":false,"acquired":false,"shares":183008,"price":6.01,"value":1099878.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.06. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon."}],"balance_after":2577387,"source":{"system":"sec-edgar","filing":"0001140361-24-013634","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124013634/form4.xml","form_type":"4"}},{"id":1574450,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-15T21:00:30.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":448276,"price":6.05,"value":2712069.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.02 to $6.20. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon."}],"balance_after":2760395,"source":{"system":"sec-edgar","filing":"0001140361-24-013634","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124013634/form4.xml","form_type":"4"}},{"id":1574449,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-15T21:00:30.000Z","date":"2024-03-13","kind":"sale","planned":false,"acquired":false,"shares":407000,"price":6.21,"value":2527470.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.13 to $6.27. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned by Aisling Capital II LP (\"Aisling\"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC (\"Aisling Partners\"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP (\"Aisling GP\"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon."}],"balance_after":3208671,"source":{"system":"sec-edgar","filing":"0001140361-24-013634","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124013634/form4.xml","form_type":"4"}},{"id":1611922,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T21:00:31.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":37541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":37541,"derivative":{"exercise_price":5.4,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":37541},"source":{"system":"sec-edgar","filing":"0001140361-24-010237","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124010237/form4.xml","form_type":"4"}},{"id":1611921,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-02-28T21:00:31.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":24040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 26,586 shares of common stock owned by the reporting person."}],"balance_after":76441,"source":{"system":"sec-edgar","filing":"0001140361-24-010237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036124010237/form4.xml","form_type":"4"}},{"id":1848071,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T16:09:11.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":31238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":31238,"derivative":{"exercise_price":1.47,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":31238},"source":{"system":"sec-edgar","filing":"0001415889-23-010090","document":"form4-06212023_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000141588923010090/form4-06212023_080601.xml","form_type":"4"}},{"id":1862917,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:32:52.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035614","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035614/doc4.xml","form_type":"4"}},{"id":1962935,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-08T21:30:43.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":51630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":51630,"derivative":{"exercise_price":3.35,"expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":51630},"source":{"system":"sec-edgar","filing":"0001140361-23-010771","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036123010771/form4.xml","form_type":"4"}},{"id":1962934,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-03-08T21:30:43.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":25815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 13,293 shares of common stock owned by the reporting person."}],"balance_after":52401,"source":{"system":"sec-edgar","filing":"0001140361-23-010771","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036123010771/form4.xml","form_type":"4"}},{"id":2224424,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T18:43:39.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":15619,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the total shares on the one year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued."}],"balance_after":15619,"derivative":{"exercise_price":1.31,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":15619},"source":{"system":"sec-edgar","filing":"0001209191-22-038760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919122038760/doc4.xml","form_type":"4"}},{"id":2255696,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:09:24.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032169/doc4.xml","form_type":"4"}},{"id":2341386,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-09T17:59:09.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":53172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":53172,"derivative":{"exercise_price":1.67,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":53172},"source":{"system":"sec-edgar","filing":"0001140361-22-008676","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036122008676/form4.xml","form_type":"4"}},{"id":2341385,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-03-09T17:59:09.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":26586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1)."}],"balance_after":26586,"source":{"system":"sec-edgar","filing":"0001140361-22-008676","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036122008676/form4.xml","form_type":"4"}},{"id":2648146,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":1936834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458360},"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648145,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Series A Preferred Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":8000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1893232},"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648144,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Common Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"purchase","acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2834910,"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648143,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Common Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":458360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2647410,"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2648142,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Common Stock","published_at":"2021-07-01T18:29:04.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":1893232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\").  Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling, and Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2189050,"source":{"system":"sec-edgar","filing":"0001209191-21-044561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121044561/doc4.xml","form_type":"4"}},{"id":2653846,"issuer":{"id":77243,"kind":"organization","name":"Elevation Oncology, Inc.","symbol":"ELEV"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member"}}],"security":"Director Stock Option","published_at":"2021-06-28T18:18:35.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":31238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. The stock option vests as of 1/36 of the total shares monthly beginning on July 24, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":31238,"derivative":{"exercise_price":16,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":31238},"source":{"system":"sec-edgar","filing":"0001209191-21-043527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000120919121043527/doc4.xml","form_type":"4"}},{"id":2669847,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T20:38:43.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.9318,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-21-012087","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761921012087/doc1.xml","form_type":"4"}},{"id":2669846,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-14T20:38:43.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units which vest in a single installment on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001567619-21-012087","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761921012087/doc1.xml","form_type":"4"}},{"id":2674437,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:55:04.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":29680,"source":{"system":"sec-edgar","filing":"0001209191-21-039632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039632/doc4.xml","form_type":"4"}},{"id":2779877,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:35:34.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":1142857,"price":1.75,"value":1999999.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are directly owned by Aisling Capital IV, LP (\"Aisling\"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose."}],"balance_after":3142857,"source":{"system":"sec-edgar","filing":"0001209191-21-021769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021769/doc4.xml","form_type":"4"}},{"id":2825762,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-01T21:02:53.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022."}],"balance_after":55000,"derivative":{"exercise_price":2.35,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001193805-21-000294","document":"e620329_4-elms.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380521000294/e620329_4-elms.xml","form_type":"4"}},{"id":2864247,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:12:23.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":17022,"source":{"system":"sec-edgar","filing":"0001209191-21-010226","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010226/doc5.xml","form_type":"5"}},{"id":3097435,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-29T21:47:22.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units which vest in a single installment on the first anniversary of June 3, 2020, subject to the Reporting Person's continued service to the Issuer on\nthe vesting date."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001140361-20-015090","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036120015090/form4.xml","form_type":"4"}},{"id":3120052,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T17:10:28.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the first anniversary of the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":1.01,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-011813","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761920011813/doc1.xml","form_type":"4"}},{"id":3165235,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T17:12:34.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193805-20-000553","document":"e619599_4a-elms.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380520000553/e619599_4a-elms.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3231402,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-03T19:11:37.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":2.915,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-20-000292","document":"e619426_4-elms.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380520000292/e619426_4-elms.xml","form_type":"4"}},{"id":3231401,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T19:11:37.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"), which will vest in equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"), which will vest in equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193805-20-000292","document":"e619426_4-elms.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380520000292/e619426_4-elms.xml","form_type":"4"}},{"id":3349952,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":2,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":3,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value of $0.0001","published_at":"2019-12-06T10:23:17.000Z","date":"2019-12-02","kind":"grant","acquired":true,"shares":689655,"price":1.45,"value":999999.75,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms."}],"balance_after":2718226,"source":{"system":"sec-edgar","filing":"0000899243-19-028646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924319028646/doc4.xml","form_type":"4"}},{"id":3443867,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-08-08T21:07:52.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a two year period commencing on September 6, 2019 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.21,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-045152","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919119045152/doc4.xml","form_type":"4"}},{"id":3459080,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-18T16:07:53.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in equal monthly installments over a twelve-month period."}],"balance_after":1500,"derivative":{"exercise_price":2.34,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001567619-19-014980","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919014980/doc1.xml","form_type":"4"}},{"id":3462033,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":2,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":3,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":4,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":5,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-15T16:15:23.000Z","date":"2019-07-15","kind":"purchase","acquired":true,"shares":2500000,"price":0.6,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Aisling Capital IV, LP (\"Aisling\"). Aisling Capital Partners IV, LP (\"Aisling GP\"), is the general partner of Aisling. Aisling Capital Partners IV LLC (\"Aisling Partners\"), is the general partner of Aisling GP. The individual managing members (\"the Aisling Managers\"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any."}],"balance_after":10100000,"source":{"system":"sec-edgar","filing":"0000899243-19-019602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000089924319019602/doc4.xml","form_type":"4"}},{"id":3556782,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":112071,"kind":"organization","name":"Aisling Capital IV, LP","position":1,"cik":"0001652910","reported_name":"Aisling Capital IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112073,"kind":"organization","name":"Aisling Capital Partners IV, LP","position":2,"cik":"0001737020","reported_name":"Aisling Capital Partners IV, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112072,"kind":"organization","name":"Aisling Capital Partners IV LLC","position":3,"cik":"0001737019","reported_name":"Aisling Capital Partners IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value of $0.0001","published_at":"2019-04-12T16:15:56.000Z","date":"2019-04-11","kind":"grant","acquired":true,"shares":428571,"price":3.5,"value":1499998.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital IV, LP (\"Aisling\"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms."}],"balance_after":2028571,"source":{"system":"sec-edgar","filing":"0000899243-19-010594","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924319010594/doc4.xml","form_type":"4"}},{"id":3592466,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-15T17:01:03.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":3.89,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193805-19-000294","document":"e618303_4-elms.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380519000294/e618303_4-elms.xml","form_type":"4"}},{"id":3653573,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:09:26.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":8750,"price":235,"value":2056250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":180.98,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001567619-19-004568","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919004568/doc1.xml","form_type":"4"}},{"id":3653572,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:09:26.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":11000,"price":235,"value":2585000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":78.58,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-19-004568","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919004568/doc1.xml","form_type":"4"}},{"id":3653571,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:09:26.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":7812,"price":235,"value":1835820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":24.18,"expiration_date":"2026-06-09","underlying":"Common Stock","underlying_shares":7812},"source":{"system":"sec-edgar","filing":"0001567619-19-004568","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919004568/doc1.xml","form_type":"4"}},{"id":3653570,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:09:26.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":7812,"price":235,"value":1835820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":20.91,"expiration_date":"2025-07-27","underlying":"Common Stock","underlying_shares":7812},"source":{"system":"sec-edgar","filing":"0001567619-19-004568","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919004568/doc1.xml","form_type":"4"}},{"id":3653569,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:09:26.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":15625,"price":235,"value":3671875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":13,"expiration_date":"2024-07-30","underlying":"Common Stock","underlying_shares":15625},"source":{"system":"sec-edgar","filing":"0001567619-19-004568","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919004568/doc1.xml","form_type":"4"}},{"id":3653568,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-15T09:09:26.000Z","date":"2019-02-15","kind":"other","acquired":false,"shares":2038920,"price":235,"value":479146200.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":2038920,"source":{"system":"sec-edgar","filing":"0001567619-19-004568","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000156761919004568/doc1.xml","form_type":"4"}},{"id":3868776,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-12T16:45:29.000Z","date":"2018-07-10","kind":"sale","acquired":false,"shares":1400000,"price":179.43,"value":251202000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":2038920,"source":{"system":"sec-edgar","filing":"0000899243-18-019810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000089924318019810/doc4.xml","form_type":"4"}},{"id":3883884,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-25T17:01:31.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":17500,"derivative":{"exercise_price":4.91,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001193805-18-000903","document":"e618128_4-elms.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380518000903/e618128_4-elms.xml","form_type":"4"}},{"id":3893576,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-14T17:01:17.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These stock options are held by Mr. Elms for the benefit of Aisling Capital LLC. Mr. Elms disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or any other purposes, except to the extent of his pecuniary interest therein."}],"balance_after":8750,"derivative":{"exercise_price":180.98,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001140361-18-028636","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036118028636/doc1.xml","form_type":"4"}},{"id":3923703,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-21T20:16:47.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the stock option vest on May 17, 2019, and the remaining underlying shares vest in equal monthly installments over the following three-year period."}],"balance_after":25000,"derivative":{"exercise_price":4.27,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001587221-18-000016","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000158722118000016/edgar.xml","form_type":"4"}},{"id":4125123,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T16:31:26.000Z","date":"2017-12-19","kind":"sale","acquired":false,"shares":250000,"price":80.5,"value":20125000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":3438920,"source":{"system":"sec-edgar","filing":"0000950142-17-002235","document":"es1701246_4-loxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217002235/es1701246_4-loxo.xml","form_type":"4"}},{"id":4150996,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-27T19:29:09.000Z","date":"2017-11-22","kind":"sale","acquired":false,"shares":500000,"price":75,"value":37500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":3688920,"source":{"system":"sec-edgar","filing":"0000950142-17-002107","document":"es1701180_4-loxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217002107/es1701180_4-loxo.xml","form_type":"4"}},{"id":4273321,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-06-23T17:18:47.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These stock options are held by Mr. Elms for the benefit of Aisling Capital LLC. Mr. Elms disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or any other purposes, except to the extent of his pecuniary interest therein."}],"balance_after":11000,"derivative":{"exercise_price":78.58,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001140361-17-026009","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000114036117026009/doc1.xml","form_type":"4"}},{"id":4288119,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-08T18:03:04.000Z","date":"2017-06-06","kind":"grant","acquired":true,"shares":53837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":53837,"derivative":{"exercise_price":3.66,"expiration_date":"2027-06-06","underlying":"Common Stock","underlying_shares":53837},"source":{"system":"sec-edgar","filing":"0001193805-17-001058","document":"e616265_4-elms.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380517001058/e616265_4-elms.xml","form_type":"4"}},{"id":4442226,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-16T20:15:34.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":10000,"derivative":{"exercise_price":5,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-17-000281","document":"e615788_4-elms.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250195/000119380517000281/e615788_4-elms.xml","form_type":"4"}},{"id":4492221,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":165043,"kind":"organization","name":"AISLING CAPITAL III LP","position":1,"cik":"0001444717","reported_name":"AISLING CAPITAL III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165044,"kind":"organization","name":"Aisling Capital Partners III LP","position":2,"cik":"0001532634","reported_name":"Aisling Capital Partners III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165045,"kind":"organization","name":"Aisling Capital Partners III LLC","position":3,"cik":"0001532635","reported_name":"Aisling Capital Partners III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61997,"kind":"person","name":"ELMS STEVE","position":4,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":5,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165046,"kind":"person","name":"Purcell Dennis J","position":6,"cik":"0001297291","reported_name":"Purcell Dennis J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-12T17:17:02.000Z","date":"2017-01-10","kind":"purchase","acquired":true,"shares":160000,"price":31,"value":4960000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Aisling Capital III, LP (\"Aisling\"), and indirectly held by Aisling Capital Partners III, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners III LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the \"Investment Committee\") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling."}],"balance_after":4188920,"source":{"system":"sec-edgar","filing":"0000950142-17-000108","document":"es1700164_4-loxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095014217000108/es1700164_4-loxo.xml","form_type":"4"}}]}